Louis Garguilo

ARTICLES BY LOUIS

  • 3/30/2020

    With your newly dispersed workforce, employees have in effect become a part of your external supply chain. How can leaders help them get through this time of uncertainty, and continue to perform at a high level? Here's some advice.

  • 3/26/2020

    In terms of increasing transparency regarding the location of production, Novartis, Regeneron, GeoVac, and Gilead are positive examples for Outsourced Pharma readers.

  • 3/20/2020

    Communication with your service providers may turn out most important in getting through immediate coronavirus-induced supply-chain challenges. Outsourcing may have got you into this situation; now it may be the only thing that can get you out. 

  • 3/18/2020

    Celgene and Shire former executive Joanne Beck joins Boston Pharmaceuticals. It's another example of where drug development is heading, and how outsourcing -- and lots of funding -- are driving programs to proof-of-concept.

  • 3/17/2020

    If drugs are discovered as purposefully held up by China to create a supply issue in the U.S., would you ever again employ a China-based CMO? Who would have thought Outsourced Pharma readers would be front and center in presidential politics? But you are.

  • 3/16/2020

    Ascending U.S.-based CDMOs may exemplify a national taking back of our own supply-chain destiny. Now there’s another CDMO, Andelyn Biosciences, taking shape in Central Ohio, and targeting gene-therapy services.

  • 3/13/2020

    The first was to be a celebration for safely, reliably, and productively keeping drug development and manufacturing supply chains running. The second is a threat to shut those supply chains down. But here’s a second irony: This new coronavirus may have provided us an opportunity of sorts. 

  • 3/11/2020

    “I’m one of the original founders at Aristea, a start-up company here in San Diego.” One of the founders? Sara McCutchan takes the conference room by surprise, although by now we should be inured to how thoroughly younger generations are contributing to our biopharma industry.

  • 3/4/2020

    “Right now, the coronavirus situation is more about transportation than manufacture,” says one biopharma executive with a global supply chain. “If this continues for more than a year, then I think it'll be getting products manufactured that will really be in play.”

  • 3/4/2020

    This is a story of drug and personal development. It demonstrates why our industry deserves respect for its accomplishments, and recognition of the individuals who drive them. And it outlines an interesting strategy for outsourcing drug development and manufacturing.

louis-g-photo-edited

Louis Garguilo



Louis Garguilo is chief editor of Outsourced Pharma, and is considered a leading authority on the art and science of drug development and manufacturing outsourcing. He studied public relations and journalism at Syracuse University (and holds a Master’s in English). His widely read editorials are based on in-depth analysis and interviews with industry executives and professionals. Editorials are written in an engaging and unique style that guide readers through the macro aspects and subtle nuances of outsourcing, and working with contract development and manufacturing organizations (CDMOs). Garguilo also serves as moderator for the various Outsourced Pharma Live webinars held throughout the year.

Prior to joining Outsourced Pharma in 2014, Garguilo spent a decade at a global pharmaceutical contract research, development and manufacturing organization, leaving the industry after attaining the role of vice president, business development and marketing. Additionally, he has served under the governor of New York in the state’s economic development agency, as liaison to the pharmaceutical/biotechnology industry; as chief strategic officer for an e-learning software company; and spent most of the ‘80s and ‘90s in Japan as an educator, author, and communications consultant.